Next Article in Journal
Recurrent Sinonasal Squamous Cell Carcinoma: Current Insights and Treatment Advances
Previous Article in Journal
The Effect of Resistance and/or Aerobic Training on Quality of Life, Fitness, and Body Composition in Prostate Cancer Patients—A Systematic Review and Meta-Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 1
10.3390/cancers17010001
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Cancers 2024, 16(15), 2669.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Peisen et al. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 2024, 16, 2669

by
Felix Peisen
1,*,
Annika Gerken
2,
Alessa Hering
2,3,
Isabel Dahm
1,
Konstantin Nikolaou
1,4,
Sergios Gatidis
1,5,
Thomas K. Eigentler
6,7,
Teresa Amaral
6,
Jan H. Moltz
2,† and
Ahmed E. Othman
8,†
1
Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Tuebingen University Hospital, Hoppe-Seyler-Straße 3, 72076 Tuebingen, Germany
2
Fraunhofer Institute for Digital Medicine MEVIS, Max-von-Laue-Straße 2, 28359 Bremen, Germany
3
Diagnostic Image Analysis Group, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands
4
Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Faculty of Medicine, Eberhard Karls University, 72076 Tuebingen, Germany
5
Max Planck Institute for Intelligent Systems, Max-Planck-Ring 4, 72076 Tuebingen, Germany
6
Center of Dermato-Oncology, Department of Dermatology, Eberhard Karls University, Tuebingen University Hospital, Liebermeisterstraße 25, 72076 Tuebingen, Germany
7
Department of Dermatology, Venereology and Allergology, Charité—Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Luisenstraße 2, 10117 Berlin, Germany
8
Institute of Neuroradiology, Johannes Gutenberg University Hospital Mainz, Langenbeckstraße 1, 55131 Mainz, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2025, 17(1), 1; https://doi.org/10.3390/cancers17010001
Submission received: 22 November 2024 / Accepted: 28 November 2024 / Published: 24 December 2024
Versions Notes

Text Correction

There was an error in the original publication [1]. Section 2.4 in the manuscript and S2.2 in the supplementary should contain the information “and presence of new metastases in first follow-up CT” for the description of the clinical features used as input.
A correction has been made to Section 2.4 in the manuscript and S2.2 in the supplementary. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Peisen, F.; Gerken, A.; Hering, A.; Dahm, I.; Nikolaou, K.; Gatidis, S.; Eigentler, T.K.; Amaral, T.; Moltz, J.H.; Othman, A.E. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 2024, 16, 2669. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Peisen, F.; Gerken, A.; Hering, A.; Dahm, I.; Nikolaou, K.; Gatidis, S.; Eigentler, T.K.; Amaral, T.; Moltz, J.H.; Othman, A.E. Correction: Peisen et al. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 2024, 16, 2669. Cancers 2025, 17, 1. https://doi.org/10.3390/cancers17010001

AMA Style

Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, Eigentler TK, Amaral T, Moltz JH, Othman AE. Correction: Peisen et al. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 2024, 16, 2669. Cancers. 2025; 17(1):1. https://doi.org/10.3390/cancers17010001

Chicago/Turabian Style

Peisen, Felix, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou, Sergios Gatidis, Thomas K. Eigentler, Teresa Amaral, Jan H. Moltz, and Ahmed E. Othman. 2025. "Correction: Peisen et al. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 2024, 16, 2669" Cancers 17, no. 1: 1. https://doi.org/10.3390/cancers17010001

APA Style

Peisen, F., Gerken, A., Hering, A., Dahm, I., Nikolaou, K., Gatidis, S., Eigentler, T. K., Amaral, T., Moltz, J. H., & Othman, A. E. (2025). Correction: Peisen et al. Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors? Cancers 2024, 16, 2669. Cancers, 17(1), 1. https://doi.org/10.3390/cancers17010001

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop